COV-ID: A LAMP sequencing approach for high-throughput co) —
detection of SARS-CoV-2 and influenza virus in human saliva	

- Robert Warneford-Thomson^{1,2,3}, Parisha P. Shah^{3,4}, Patrick Lundgren⁵, Jonathan Lerner³,
 Benjamin S. Abella⁶, Kenneth S. Zaret^{2,3}, Jonathan Schug⁷, Rajan Jain^{3,4}, Christoph A. Thaiss⁵,
 and Roberto Bonasio^{2, 3*}.
- 14

- 15
- ¹Graduate Group in Biochemistry and Biophysics, University of Pennsylvania Perelman School of
- 17 Medicine, Philadelphia, PA, USA
- ²Epigenetics Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
 USA
- ³Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of
- 21 Medicine, Philadelphia, PA, USA
- ⁴Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia,
 PA, USA
- ⁵Department of Microbiology, University of Pennsylvania Perelman School of Medicine,
 Philadelphia, PA, USA
- ⁶Department of Emergency Medicine and Penn Acute Research Collaboration, University of
 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- ⁷Next-Generation Sequencing Core, Department of Genetics, University of Pennsylvania
 Perelman School of Medicine, Philadelphia, PA, USA
- 30
- 31
- ^{*}Lead contact, to whom correspondence should be addressed: roberto@bonasiolab.org.

33 ABSTRACT

34 The COVID-19 pandemic has created an urgent need for rapid, effective, and low-cost SARS-35 CoV-2 diagnostic testing. Here, we describe COV-ID, an approach that combines RT-LAMP with 36 deep sequencing to detect SARS-CoV-2 in unprocessed human saliva with high sensitivity (5-10 37 virions). Based on a multi-dimensional barcoding strategy. COV-ID can be used to test thousands 38 of samples overnight in a single sequencing run with limited labor and laboratory equipment. The 39 sequencing-based readout allows COV-ID to detect multiple amplicons simultaneously, including 40 key controls such as host transcripts and artificial spike-ins, as well as multiple pathogens. Here 41 we demonstrate this flexibility by simultaneous detection of 4 amplicons in contrived saliva 42 samples: SARS-CoV-2, influenza A, human STATHERIN, and an artificial SARS spike-in. The 43 approach was validated on clinical saliva samples, where it showed 100% agreement with RTgPCR. COV-ID can also be performed directly on saliva adsorbed on filter paper, simplifying 44 45 collection logistics and sample handling.

46 INTRODUCTION

47 Within the first year of the COVID-19 pandemic SARS-CoV-2 has swept across the world, leading 48 to more than 130 million infections and over 2.8 million deaths worldwide (as of April 2021). In 49 many countries, non-pharmaceutical interventions, such as school closures and national lockdowns, have proven to be effective, but could not be sustained due to economic and social 50 impact^{1, 2}. Regularly performed population-level diagnostic testing is an attractive solution³, 51 52 particularly as asymptomatic individuals are implicated in rapid disease transmission, with a 53 strong overdispersion in secondary transmission⁴. Maintenance of population-level testing can be 54 successful in isolating asymptomatic individuals and preventing sustained transmission^{5, 6}; 55 however, considerable barriers exist to the adoption of such massive testing strategies. Two such 56 barriers are cost and supply constraints for commercial testing reagents, both of which make it 57 impractical to test large numbers of asymptomatic individuals on a recurrent basis. A third major 58 barrier is the lack of "user-friendly" protocols that can be rapidly adopted by public and private 59 organizations to establish high-throughput surveillance screening. In addition, while COVID-19 testing of symptomatic individuals might be effective during the summer season, when other 60 61 respiratory infections are rare, new strategies are needed to facilitate rapid differential diagnosis 62 between SARS-CoV-2 and other respiratory viruses in winter.

63 Recent adaptations of reverse transcription and polymerase chain reaction (RT-PCR) to amplify 64 viral sequence and perform next-generation DNA sequencing have opened promising new 65 avenues for massively parallel SARS-CoV-2 detection. In general, sequencing-based protocols 66 use libraries of amplification primers to tag reads originating from each individual patient sample 67 with a unique index that can be identified and deconvoluted after sequencing, thus allowing pooling of tens of thousands of samples in a single assay. SARSeg, SPAR-Seg, Swab-seg, and 68 INSIGHT, directly amplify the viral RNA by RT-PCR and simultaneously introduce barcodes⁷⁻¹⁰. 69 70 While effective, these methods rely on individual PCR amplification of each patient sample, thus 71 requiring a large number of thermal cyclers for massive scale-up. An alternative approach, 72 ApharSeq, addresses this bottleneck by annealing barcoded RT primers to viral RNA and pooling 73 samples prior to amplification but the need for specialized oligo-dT magnetic beads might 74 constitute a separate adoption barrier for this method¹¹. Finally, several recent methods have been designed to take advantage of the extreme sensitivity and isothermal conditions of loop-75 mediated isothermal amplification (LAMP)¹²⁻¹⁴, but these methods either require additional 76 manipulation to introduce barcodes^{12, 13} or do not allow for convenient multiplexing¹⁴. 77

In this study, we present COV-ID, a method for SARS-CoV-2 identification based on LAMP, which enables large-scale diagnostic testing at low cost and with minimal on-site equipment. COV-ID is a robust method that can be used to test tens of thousands of samples for multiple pathogens with modest reagent costs and 2–4 laboratory personnel, generating results within 24 hours. COV-ID uses unpurified saliva or saliva adsorbed on filter paper as input material, thus enabling the massively parallel, inexpensive testing required for population-level surveillance of the COVID-19 pandemic (**Fig. 1A**).

85 RESULTS

86 Two-step amplification and indexing of viral and human sequences via RT-LAMP and PCR

The molecular basis for COV-ID is reverse transcription loop-mediated isothermal amplification (RT-LAMP), an alternative to PCR that has been used extensively for viral DNA or RNA detection in clinical samples¹⁵⁻¹⁸, including SARS-CoV-2^{19, 20}. RT-LAMP requires 4–6 primers that recognize different regions of the target sequence^{21, 22} and proceeds through a set of primed and self-primed steps to yield many inverted copies of the target sequence spanning a range of molecular sizes (**Fig. S1**). The forward inner primer (FIP) and backward inner primer (BIP), which recognize

93 internal sequences, are incorporated in opposite orientation across the target sequence in the94 final amplified product (Fig. S1).

95 Previous studies have shown that the FIP and BIP tolerate insertion of exogenous sequence between their different target homology regions²³. We exploited this flexibility and introduced 1) 96 patient-specific barcodes as shown previously^{12, 14, 23} and 2) artificial sequences that allowed for 97 98 PCR amplification of a small product compatible with Illumina sequencing library construction 99 (Fig. 1, Fig. S1). These innovations allow us to pool individually barcoded RT-LAMP reactions 100 and amplify them in batch via PCR, while introducing unique P5 and P7 dual indexes in different 101 pools, thus enabling two-dimensional barcoding and dramatically increasing method throughput 102 (see **Table S1** for PCR primer sequences). To minimize pool variability, PCR primers can be 103 titrated to 100 nM and pooled PCRs carried out to completion, resulting in each pool being 104 amplified to the same approximate concentration. Uniquely amplified and barcoded pools are 105 mixed into a single "super-pool" that can be sequenced on an Illumina NextSeq or similar 106 instrument (Fig. 1A). Combining individual barcodes embedded in the product at the RT-LAMP 107 step with dual indexes introduced at the pool level during the PCR step allows for deconvolution 108 of thousands or tens of thousands of samples in a single sequencing run.

109 To determine whether introduction of these exogenous sequences into the primers inhibited the 110 isothermal amplification step, we performed RT-LAMP on inactivated SARS-CoV-2 virus using an 111 extensively validated primer set against the N2 region of the nucleocapsid protein²⁴ including 112 either the conventional BIP and FIP primers or their modified version re-engineered for the COV-113 ID workflow (Fig. 1B). Although the appearance of the amplified viral product was slightly delayed 114 when using COV-ID primers, all reactions reached saturation rapidly and without detectable 115 amplification of negative controls (Fig. 1C). Next, we tested whether COV-ID was compatible with 116 RT-LAMP using newly designed primers against a host (human) transcript and whether the 117 second step of COV-ID, direct library construction and indexing via PCR amplification (Fig. 1D). 118 yields the desired product. For this, we designed RT-LAMP primers against the human beta-actin 119 (ACTB) transcript that included sequences necessary for COV-ID. After RT-LAMP, reactions were 120 diluted 100-fold before PCR with barcoded Illumina adapters. A PCR product of the expected size 121 was visible in reactions containing total HeLa RNA, whereas no PCR product was observed in 122 the absence of template (Fig. 1E). Sanger sequencing of the PCR product confirmed that RT-123 LAMP followed by PCR generated the product expected by the COV-ID method design, including 124 the sample barcode introduced during the RT-LAMP step.

125 Thus, our data show that RT-LAMP is tolerant of sequence insertions in the BIP and FIP primers 126 that allow introduction of LAMP-level barcodes as well as sequences homologous to Illumina 127 adapters for direct amplification, indexing, and library construction via PCR.

128 Sequencing-based detection of SARS-CoV-2 RNA from saliva using COV-ID

129 We next evaluated the utility of COV-ID to detect viral RNA in saliva. Saliva is an attractive sample material for COVID-19 diagnostics with potential for early detection²⁵, and has been shown to be 130 a viable template for nucleic acid amplification via RT-PCR²⁶, recombinase polymerase 131 amplification (RPA)²⁷ as well as RT-LAMP^{28, 29}. We prepared human saliva for RT-LAMP using a 132 133 previously described treatment that inactivates SARS-CoV-2 virions, saliva-borne RNases and LAMP inhibitors (Fig. 2A)²⁹. We performed RT-LAMP followed by PCR on inactivated saliva 134 135 spiked with water or 1,000 total copies of inactivated SARS-CoV-2 virus. We observed a single 136 band of the expected size in reactions performed on saliva spiked with virus but not in control 137 reactions (Fig. 2B). The sequence of the amplified and barcoded viral product was confirmed by 138 Sanger sequencing (Fig. S2A). Next, we subjected the libraries to deep sequencing. Reads 139 aligned uniformly to the N gene, the region targeted by the N2 primer set, in COV-ID libraries 140 constructed from viral samples but not in control libraries (Fig. 2C).

141 In several SARS-CoV-2 FDA approved tests, parallel amplification of a host (human) amplicon is 142 implemented as a metric for sample integrity and guality. That is, if no human RNA is amplified from a clinical sample, no conclusion can be drawn from a negative test result³⁰. However, in most 143 144 tests, viral and human amplicons must be detected separately, resulting in a multiplication of the 145 number of reactions to be performed. We reasoned that the deep sequencing nature of COV-ID 146 would allow for simultaneous detection of viral, human, and other control amplicons, without 147 increasing the number of necessary reactions. In fact, given that the PCR handles inserted in the 148 BIP and FIP are the same for all RT-LAMP amplicons (Fig. 1B), the same P5 and P7 Illumina 149 primers allow the simultaneous amplification of all RT-LAMP products obtained with COV-ID-150 modified primer sets (Fig. 1D). To identify a suitable human control, we compared conventional RT-LAMP primers for the mRNA of ACTB²⁴ or STATHERIN (STATH), a gene expressed 151 specifically in saliva³¹. To determine which of the two RT-LAMP primer sets was a better proxy to 152 153 measure RNA integrity in saliva samples, we assayed for amplification of the respective products 154 in presence or absence of RNase. Whereas addition of RNase A abolished the STATH signal, it 155 was ineffectual for ACTB (Fig. S2B), suggesting that amplification of genomic DNA made 156 considerable contributions to the RT-LAMP signal observed for the latter. Therefore, we utilized 157 STATH mRNA as a human control in subsequent experiments.

158 We used COV-ID-adapted primer sets for N2 and STATH (Table S1) in multiplex on inactivated 159 saliva spiked with a range of SARS-CoV-2 from 5 to 10,000 virions/µL. Subsequently, each RT-160 LAMP reaction was separately amplified via PCR using a unique P5 and P7 index combination. 161 pooled, guantified, and deep-sequenced to an average depth of 6,000 reads per sample. After 162 read trimming, alignment, and filtering (see Methods), 76% of reads from saliva COV-ID reactions 163 were informative (Fig. S2C). In order to differentiate SARS-CoV-2 positive and negative samples, 164 we calculated the ratio between N2 reads and reads mapping to the human STATH control. Using 165 the highest N2/STATH read ratio in control (SARS-CoV-2 negative saliva) as a threshold, 95% 166 (19/20) of samples with spiked-in virus were correctly classified as positives (Fig. 2D). Using 167 COV-ID, we consistently detected SARS-CoV-2 in saliva samples containing as low as 5 virions 168 per µL, a sensitivity comparable and in some cases superior to those of established testing 169 protocols³².

170 Scaling COV-ID to handle higher sample numbers requires pooling samples immediately 171 following RT-LAMP, prior to the PCR step (Fig. 1A). We designed 32 unique 5-nucleotide 172 barcodes for several target LAMP amplicons (Fig. S2D and Table S2). We first individually 173 validated each barcode and primer combination by real-time fluorescence and PCR efficiency. 174 Certain barcodes inhibited the RT-LAMP reaction, possibly due to internal micro-homology and primer self-hybridization³³. Nonetheless, out of 32 barcodes tested in 3 separate RT-LAMP 175 176 reactions (N2, ACTB, and STATH), 25 successfully amplified all three target RNAs (Fig. S2D). 177 Saliva samples spiked with various concentrations of inactivated SARS-CoV-2 were amplified via 178 barcoded RT-LAMP, then optionally pooled prior to PCR and sequencing (Fig. S2E). CoV-179 2/STATH ratios demonstrated no loss of sensitivity or specificity in the pooled samples compared 180 to the individual PCRs.

To test the potential of COV-ID on patient samples, we tested saliva specimens, collected and previously analyzed at the Hospital of the University of Pennsylvania (see Methods). We carried out multiplex barcoded RT-LAMPs on each sample (COV-ID step I, **Fig. 1B**), pooled the reactions and then constructed libraries via PCR (COV-ID step II, **Fig. 1D**). After deep sequencing, analysis of *N2/STATH* ratios showed 100% (8/8) concordance with viral copy numbers generated by a standard clinical test (RNA purification followed by RT-qPCR) (**Fig. 2E**), demonstrating the effectiveness of the COV-ID approach.

Taken together, our data show that COV-ID can be utilized to detect viral and human amplicons
in multiplex directly from saliva. The samples that can be batch amplified and deconvoluted after
deep sequencing.

191 Calibration of COV-ID using an artificial spike-in

192 Existing deep sequencing approaches for massively parallel COVID-19 testing based on RT-PCR 193 incorporate artificial spike-ins, which serve as an internal calibration controls and allow for better estimates of viral loads by end-point PCR^{7,8}. At the same time, adding to the reactions an artificial 194 195 substrate for amplification helps minimizing spurious signals as it can "scavenge" viral 196 amplification primers in negative samples. Finally, by providing a baseline amplification even in 197 empty samples, a properly designed spike-in strategy can reduce variance in total amounts of 198 final amplified products across samples, which compresses the dynamic-range of sequence 199 coverage for each patient in a complex pool and, therefore, reduces the risk of inconclusive 200 samples due to low sequencing coverage⁸.

201 We reasoned that a spike-in approach for LAMP-based quantification would provide similar 202 benefits in the context of COV-ID. To generate a SARS-CoV-2 spike-in, we synthesized a 203 fragment of the N2 RNA that retained all primer-binding regions for RT-LAMP and contained a 204 divergent 7-nt stretch of sequence to distinguish reads originating from the spike-in from those 205 originating from the natural virus (Fig. S3A). After confirming that the spike-in template was 206 efficiently amplified via RT-LAMP with the N2 primer set (Fig. S3B), we performed pooled COV-207 ID on virus-containing saliva in the presence of 20 fg of N2 spike-in RNA. As expected⁸, addition 208 of a constant amount of viral spike-in across reactions reduced the variability in total read numbers 209 for individual samples in the final pool (Fig. S3C). As discussed above, a narrower range in 210 sequencing output across samples in a pool optimizes the utilization of sequencing reads, and 211 ultimately lowers the cost per sample. Because the spike-in provides an internal calibration that 212 is independent of the RNA quality found in saliva, in several cases normalization against the 213 spike-in resulted in lower levels of false positive signal from negative samples (Fig. S3D). This is 214 likely because in cases where very few STATH reads were obtained, possibly due to degradation 215 of host RNA in the saliva sample, the resulting small denominator inflated the N2/STATH ratio 216 even for SARS-CoV-2 signal that was low in absolute terms and likely spurious.

Thus, these data show that spike-in strategies are compatible with the COV-ID workflow and provide a means to stabilize total amplification and read allocation per sample while also offering an additional calibration control to better estimate the viral load in samples where the endogenous *STATH* mRNA might be below detection due to improper collection or handling.

221

223 Simultaneous detection of SARS-CoV-2 and influenza A by COV-ID

224 Given the challenge of distinguishing early symptoms of COVID-19 from other respiratory 225 infections, we evaluated COV-ID for the simultaneous detection of more than one viral pathogen. 226 Multiple distinct products can be simultaneously amplified by RT-LAMP in the same tube by 227 providing the appropriate primer sets in multiplex, as we demonstrated above by co-amplifying 228 N2 and STATH in the same COV-ID reaction (see Fig. 2). In fact, simultaneous detection of 229 SARS-CoV-2 and influenza virus by RT-LAMP was previously achieved, albeit in a fluorescent-230 based, low-throughput type of assay³⁴. We reasoned that the sequencing-based readout of COV-231 ID would allow extending this approach to the simultaneous detection of multiple pathogens as 232 well as endogenous (host mRNA) and artificial (spike-in) calibration standards, all in a single 233 reaction.

234 To test the ability of COV-ID to simultaneously detect multiple viral templates, we selected and 235 validated a generic "flu" RT-LAMP primer set that recognizes several strains, including influenza A virus (IAV) and influenza B^{34, 35}, and modified the BIP and FIP sequence to introduce the COV-236 237 ID barcodes and handles for PCR (Fig. S2D and Table S1). We added inactivated SARS-CoV-2 238 virus (BEI resources) and IAV strain H1N1 RNA (Twist Biosciences) to saliva according to a 3 x 239 4 matrix of $(10^4, 10^3, \text{ or } 0 \text{ copies per } \mu\text{L})$ SARS-CoV-2 RNA against H1N1 RNA $(10^5, 10^4, 10^3, \text{ or } 10^3,$ 240 0 copies per µL) (Fig. 3A), as well as the N2 spike-in control. We performed multiplex COV-ID on 241 these samples using primers sets for STATH, N2 (to detect SARS-CoV-2), and IAV (to detect 242 H1N1) and sequenced to an average depth of 21,000 reads per sample. Both H1N1 and SARS-243 CoV-2 were detected above background and the signal correlated with the amount of the 244 respective template added to saliva (Fig. 3B-C). Overall, multiplex COV-ID correctly identified 245 samples that contained only SARS-CoV-2 (7/8) or H1N1 (6/8). For samples that contained both 246 pathogens we observed reduced sensitivity (11/16 identification of both pathogens), which was 247 also observed in a previous multiplexing attempt³⁴. However, in practice individuals who are 248 simultaneously infected with both viruses presumably would be rare, and for these cases the 249 ability to detect at least one virus successfully would allow to follow up with further diagnostic 250 testing. We found that of the samples containing both viruses, 16/16 showed positive detection of 251 at least one pathogen (SARS-CoV-2 or H1N1), suggesting the reduced sensitivity of the multiplex 252 assay is due to interference between amplification of both viral templates. This also demonstrates 253 that COV-ID can be used as an effective screening approach for multiple viral templates.

254

255 Paper-based saliva sampling for COV-ID

As an additional step toward increasing the throughput of the COV-ID approach, we explored avenues to simplify collection, lower costs, and expedite processing time. Absorbent paper is an attractive alternative to sample vials for collection, given its low cost, wide availability, and smaller environmental footprint. In fact, paper has been used as a means to isolate nucleic acid from biological samples for direct RT-PCR testing³⁶ as well as RT-LAMP^{37, 38}.

261 We sought to determine whether the COV-ID workflow would be compatible with saliva collection 262 on absorbent paper. First, we immersed a small square of Whatman filter paper into water 263 containing various dilutions of inactivated SARS-CoV-2. After 2 min, the paper was removed and 264 transferred to PCR strip tubes followed by heating at 95°C for 5 minutes to air-dry the sample 265 (Fig. 4A). Next, we added the RT-LAMP mix containing the N2 COV-ID primer set directly to the 266 tubes containing the paper squares and let the reaction proceed in the usual conditions. COV-ID PCR products of the correct size were evident in all samples containing viral RNA, with sensitivity 267 268 of at least 100 virions / µL (Fig. 4B) and in none of the controls, demonstrating that the presence 269 of paper does not interfere with the RT-LAMP reaction and subsequent PCR amplification with 270 Illumina adapters.

271 To assay direct COV-ID detection from saliva on paper, we saturated Whatman filter paper 272 squares with saliva containing different amounts of inactivated SARS-CoV-2 virus, which, we 273 reasoned, would be equivalent to a patient collecting their own saliva by chewing on a small piece 274 of absorbent paper. Next, we placed the paper squares into reaction tubes containing 275 TCEP/EDTA inactivation buffer (see Methods) similar to that used for the in-solution samples 276 used in our previous experiments (see Fig. 1A). We dried the paper at 95°C and performed RT-277 LAMP followed by PCR (Fig. 4C), which resulted in the appearance of COV-ID products of the 278 correct size starting from saliva spiked with as few as 50 virions / µL (Fig. 4D). We then performed 279 COV-ID sequencing on saliva collected on paper using primers N2 and STATH in the presence 280 of the N2 spike-in RNA. The sequence data showed more variability and limited coverage of the 281 control amplicons compared to in-solution COV-ID likely due to the more challenging reaction 282 conditions; therefore, we normalized viral reads using both STATH and spike-in. This paper-283 based COV-ID proof-of-principle experiment detected the presence of viral RNA in samples with 284 as little as 320 copies / µL (Fig. 4E), a lower sensitivity compared to that of in-solution COV-ID but still well within the useful range³⁹ to detect infections. 285

Taken together, these data show that the RT-LAMP step of COV-ID is compatible with the presence of paper in the reaction tube and suggest that self-collection of saliva by patients directly

288 on absorbent paper could provide a simple and cost-effective strategy to collect and test 289 thousands of saliva samples for multiple pathogens (**Fig. 4F**).

290 **DISCUSSION**

291 Testing strategies are vital to an effective public health response to the COVID-19 pandemic. 292 particularly with the spread of the disease by asymptomatic individuals. An ongoing challenge to 293 COVID-19 testing is the need for massive testing strategies for population-level surveillance that 294 are needed for efficient contact tracing and isolation. Most FDA-approved clinical SARS-CoV-2 295 diagnostic tests are based on time-consuming and expensive protocols that include RNA purifications and RT-PCR³² and must be performed by trained personnel in well-equipped 296 297 laboratories. Point-of-care antigen tests provide a much faster turnaround time and require little 298 manipulation, but there remains limited data on their specificity in real-world applications⁴⁰. 299 Because of reagent limitations and diagnostic testing bottlenecks, prioritization of COVID 300 diagnostic testing continues to be for symptomatic individuals and individuals who are particularly 301 vulnerable for infection after exposure⁴¹. Private organizations, including colleges and 302 universities, have circumvented some of these challenges by contracting with private laboratories 303 to establish asymptomatic surveillance testing protocols; this is a costly option for population-level 304 surveilling of asymptomatic SARS-CoV-2 infections.

Several effective COVID-19 vaccines have been developed and there is a concerted ongoing global vaccination effort, providing a concrete means to end the pandemic. Despite this progress there are several potential risks that require vigilance: possible COVID-19 transmission in vaccinated individuals, emergence of vaccine-resistant viral variants, and public skepticism of vaccines or faltering compliance with social distancing guidelines⁴². For these reasons ongoing testing and surveillance efforts will remain important for the foreseeable future, both to monitor the progress of vaccination in reducing symptomatic cases and to detect emerging variants.

In order to scale testing to an effective volume and frequency, surveillance tests must demonstrate the following qualities: 1) <u>sensitivity</u>, to identify both asymptomatic and symptomatic carriers; 2) <u>simplicity</u> in methodology, to be performed in a number of traditional diagnostic laboratories, without specialized equipment; 3) <u>low cost</u> and easily accessible reagents; 4) <u>ease</u> <u>of collection</u> method; 5) <u>rapid</u> turnaround time to allow for isolation and contract tracing; and 6) ability to <u>co-detect</u> multiple respiratory viruses, given the overlap in patient symptoms. To this end, we have developed COV-ID, an RT-LAMP-based parallel sequencing SARS-CoV-2

detection method that can provide results from tens of thousands of samples per day at relativelylow cost to simultaneously detect multiple respiratory viruses.

321 COV-ID features several key innovations that make it well-suited to high-throughput testing. First, COV-ID uses a two-dimensional barcoding strategy⁸, where the same 96 barcodes are used in 322 323 each RT-LAMP plate, making it possible to pre-aliguot barcodes in 96-well plates ahead of time 324 and store them at -20°C, simplifying execution of the assay and shortening turnaround times. 325 Second, since RT-LAMP does not require thermal cycling, tens of thousands of samples can be 326 run simultaneously in a standard benchtop-sized incubator or hybridization oven held at 65°C. 327 Third, individual samples are pooled immediately following RT-LAMP; therefore, a single 328 thermocycler has the potential to process up to 96 or 384 RT-LAMP plates, generating 9,216 or 329 36,864 individually barcoded samples, respectively (Fig. 1A, 4F, 4G). Only 96 unique FIP 330 barcodes are required for this scaling; here, we show that 28 out of 32 LAMP barcodes tested 331 were functional for both N2 and STATH. This proof-of-principle experiment demonstrates the 332 feasibility of generating the library of barcodes required to apply COV-ID to a large population. An 333 additional advantage of sequencing-based approaches, such as COV-ID is that with carefully 334 designed primers it would be possible to recover information about viral variants directly from the 335 sequencing reads⁴³. Finally, COV-ID can generate ready-to-sequence libraries directly from saliva 336 absorbed onto filter paper, which would allow for major streamlining of the often-challenging 337 logistical process of sample collection (Fig. 4). Thus, COV-ID libraries for thousands and tens of 338 thousands of samples can be generated with relatively minimum effort in biological laboratories 339 with basic equipment and easily accessible reagents.

340 With the average throughput of an Illumina NextSeg 500/550, a relatively affordable next-341 generation sequencer up to 9,216 (96 RT-LAMPs x 96 pools) can be sequenced at a depth of 342 ~48,000 reads per sample, and up to 36,864 (96 RT-LAMPs x 384 pools) can be sequenced at a 343 depth of ~12,000 reads, which, we showed, is more than sufficient to obtain information about 344 multiple viral and control amplicons. Considering that reagents for one NextSeg run cost ~1,500 345 U.S. dollars, the theoretical sequencing cost per sample could be as low as \$0.04 (Fig. 4G). While 346 sequencing instruments are relatively specialized and not ubiquitous, amplified COV-ID DNA 347 libraries could be shipped to remote facilities for sequencing in a cost-effective manner as previously proposed by the inventors of LAMP-seq¹⁴. Finally, because of the limited sequence 348 349 space against which reads must be aligned, computational analysis of the resulting data can be 350 performed in a matter of minutes with optimized pipelines, providing results shortly after the 351 sequencing run has completed.

352 COV-ID has sensitivity of 5–10 virions of SARS-CoV-2 per μ L in contrived saliva samples (**Fig.** 353 **2D**) and at least 300 virions / μ L in saliva collected from patients in a clinical setting (**Fig. 2E**). 354 However, this was sufficient to properly classify 100% of the clinical samples analyzed, given that 355 all positive samples had an estimated viral load > 300 virions / μ L. Importantly, this was also the 356 apparent limit of sensitivity of paper-based COV-ID (**Fig. 4E**), suggesting that even in these 357 settings COV-ID would be capable of accurately classifying the majority of patient-derived 358 samples.

359 In conclusion, COV-ID is a flexible platform that can be executed at varying levels of scale with 360 additional flexibility in sample input, making it an attractive platform for surveillance testing. 361 Population-level monitoring of SARS-CoV-2 infections will be critical while vaccines are being 362 distributed to the global population, and continued surveillance will likely remain an effective 363 strategy to protect immune-compromised and unvaccinated members in society and within 364 entities and organizations where regular monitoring is critical to social isolation strategies. To that 365 end, effective, low-cost, multiplexed, and readily-implementable strategies for surveillance 366 testing, such as COV-ID, are important to mitigate the effects of the current and future pandemics.

367 METHODS

368 **RT-LAMP primer design**

Primers against *ACTB* were designed using PrimerExplorerV5 (<u>https://primerexplorer.jp/e/</u>) using
 default parameters and including loop primers (**Table S1**).

For COV-ID, priming sequences for PCR were inserted in FIP and BIP primers between the target homology regions (F1c and F2, and B1c and B2, respectively, see **Fig. S1**). After testing, we determined that 12 nts and 11 nts were most effective for the P5 and P7 binding regions, respectively, being the shortest insertion that allowed reliable PCR amplification from LAMP products without impacting LAMP efficiency. In addition a 5 nt barcode sequence was inserted at the immediate 3' end of the P5-binding region of the FIP primer.

377 LAMP barcode design

Starting from the total possible 1,024 unique 5-nt barcodes, we removed those that matched any
sequence within the RT-LAMP primers used in this study (**Table S1**) in either sense or anti-sense
orientation. From the remaining pool, we selected 32 barcodes with hamming distance of at least
2 between all candidates. We tested FIPs incorporating candidate barcodes for *ACTB*, *STATH*,

N2, and IAV primer sets on saliva RT-LAMP with 1,000 copies target amplicon. Primers that failed
 to show LAMP signal by real time fluorescence monitoring or generate expected PCR product
 were discarded. Final usable barcodes are provided in (Table S2).

385 Saliva preparation

We prepared 100x TCEP/EDTA buffer (250 mM TCEP, 100 mM EDTA, 1.15 N NaOH) ²⁹. TCEP/EDTA buffer was added to human saliva at 1:100 volume, then samples were capped, vortexed to mix and heated in a thermocycler (95°C 5 min, 4°C hold) until ready to use for RT-LAMP. When indicated, heat-inactivated SARS-CoV-2 (BEI Resources Cat. NR-52286) or H1N1 genomic RNA (Twist Biosciences Cat. 103001) was added to inactivated saliva prior to RT-LAMP.

391 N2 spike-in synthesis

To prepare the *in vitro* transcription template for SARS-CoV-2 *N2* spike-in RNA, we performed RT-PCR using Power SYBR RNA-to-Ct kit (Thermo Cat. 4389986) of heat inactivated SARS-CoV-2 (BEI Resources Cat. NR-52286) using the following primers: N2-B3 and N2-spike-T7 S. PCR product was purified and used as a template for in vitro transcription using HiScribe T7 transcription kit (NEB Cat. E2040S). RNA was purified with Trizol (Thermo Cat. 15596026), quantified via A₂₆₀, then aliquoted in BTE buffer (10 mM bis-tris pH 6.7, 1 mM EDTA) and stored at -80°C. Primers used and final spike-in sequence are provided in **Table S1**.

399 RT-LAMP

400 All RT-LAMP reactions were set up in clean laminar flow hoods and all steps before and after 401 LAMP were carried out in separate lab spaces to avoid contamination. RT-LAMP reactions were 402 set up on ice as follow: for each amplicon 5 or 6 LAMP primers were combined into 10x working 403 stock at established concentrations: 16 µM FIP, 16 µM BIP, 4 µM LF, 4 µM LB, 2 µM F3, 2 µM 404 B3. For multiplexed COV-ID reactions 10x working primer mixes for each amplicon were either 405 added proportionally so that the total primer content remained constant, or mixed so that BIP and 406 FIP primers were scaled down depending on amplicon number while remaining primers (LF 407 and/or LB, F3, B3) were kept at same concentration as in single reactions.

Each 10 μL RT-LAMP reaction mix consisted of 1x Warmstart LAMP 2x Master Mix (NEB Cat.
E1700S), 0.7 μM dUTP (Promega Cat. U1191), 1 μM SYTO-9 (Thermo Cat. S34854), 0.1 μL
Thermolabile UDG (Enzymatics Cat. G5020L), 1 μL of saliva template and optionally 20 fg of N2
Spike RNA. Reactions were prepared in qPCR plates or 8-well strip tubes, sealed, vortexed and
centrifuged briefly, then incubated in either a QuantStudio Flex 7 or StepOnePlus instrument

- (Thermo) for 65°C 1 hr. Real-time fluorescence measurements were recorded every 30 sec to
 monitor reaction progress but were not used for data analysis. Following LAMP the reactions were
- 415 heated at 95°C 5 min to inactivate LAMP enzymes.

416 Library construction by PCR amplification

417 All post-LAMP steps were carried out on a clean bench separate from LAMP reagents and 418 workspace. For individual LAMP samples, LAMP amplicons were diluted either 1:100 or 1:1,000 419 in water. For pooling of individually barcoded LAMP reactions, equal amounts of all LAMP 420 reactions were combined and then either diluted 1:1000 or purified via SPRIselect beads 421 (Beckman Coulter Cat. B23317) using a bead-to-reaction ratio of 0.1x. Purified material was 422 diluted to final 100-fold dilution relative to LAMP.

423 1 μL of diluted LAMP material was used as a template for PCR using OneTaq DNA polymerase 424 (NEB Cat. M0480L) with 100 nM each of custom dual-indexed Illumina P5 and P7 primers in 425 either 10 or 25 μL reaction (**Table S1**). PCR reactions were incubated as follows: (25 cycles of 426 stage 1 [94°C x 15 sec, 45°C x 15 sec, 68°C x 10 sec], 10 cycles of Stage 2 [94°C x 15 sec, 68°C 427 x 10 sec], 68°C x 1 min, 4°C x ∞). Note, for initial pilot COV-ID and clinical sample experiments 428 (**Fig. 2D–E**, **Fig. S2C**) PCR incubation was performed as above with modification: [Stage 1 x 10 429 cycles, Stage 2 x 25 cycles].

PCR products were resolved on 2% agarose gel to confirm library size, then all were pooled and
purified via MinElute PCR purification kit (Qiagen Cat. 28004) and quantified using either Qubit
dsDNA High Sensitivity kit (Thermo Cat. Q32851) or Kapa Library Quantification Kit for Illumina
(Kapa Cat. 07960140001).

434 Human samples

435 Clinical saliva samples used for Fig. 2E were obtained and characterized as part of a separate study at the University of Pennsylvania⁴⁴ and collected under Institutional Review Board (IRB)-436 437 approved protocols (IRB protocol #842613 and #813913). Briefly, salivary samples were collected 438 from possible SARS-CoV-2 positive patients at one of three locations: (1) Penn Presbyterian 439 Medical Center Emergency Department, (2) Hospital of the University of Pennsylvania 440 Emergency Department, and (3) Penn Medicine COVID-19 ambulatory testing center. Inclusion 441 criteria including any adult (age > 17 years) who underwent SARS-CoV-2 testing via standard 442 nasopharyngeal swab at the same visit. Patients with known COVID-19 disease who previously 443 tested positive previously were excluded. After verbal consent was obtained by a trained research

444 coordinator, patients were instructed to self-collect saliva into a sterile specimen container which445 was then placed on ice until further processing for analysis.

- 446 The saliva used in the remaining experiments was donated by one of the authors. Because it was
- 447 only used for protocol optimization the Penn IRB has determined that it did not constitute human
- 448 subjects research and therefore approval was not required.

449 Paper COV-ID

- Squares of Whatman no. 1 filter paper (2 mm x 2 mm) were cut using a scalpel on a clean surface under a laminar flow hood and stored at room temperature until used. Using ethanol-sterilized fine-nosed tweezers a single square was dipped twice into unprocessed, freshly collected saliva with or without added SARS-CoV-2 (BEI Resources Cat. NR-52286) until saliva was saturated on paper by eye. Paper was then transferred to well of 96-well plate containing 10 ul of 1x TCEP/EDTA buffer (2.5 mM TCEP, 1 mM EDTA, 1.15 NaOH). Plate was placed on heat block inside laminar flow hood or inside open thermocycler and incubated at 95°C x 10 min.
- 457 10 ul RT-LAMP mixture was prepared as described above in the absence of the N2 Spike RNA.
- 458 10 ul of RT-LAMP reaction mixture was added to each paper strip, then plate was sealed and
- 459 incubated 65°C x 1 hr, 95°C x 5 min in QuantStudio Flex 7 (Thermo). 1 ul of each reaction was
- 460 either diluted 1:100 or purified via SPRIselect beads and PCR amplified as described above.

461 Sequencing

Libraries were sequenced on one of the following Illumina instruments: MiSeq, NextSeq 500, NextSeq 550, NovaSeq 6000 and sequenced using single end programs with a minimum of 40 cycles on Read 1 and 8 cycles for index 1 (on P7) and index 2 (on P5).

465 Sequence Analysis

Reads were filtered for optical quality using FASTX-toolkit utility fastq quality filter 466 (http://hannonlab.cshl.edu/fastx toolkit/), then cutadapt45 was used to remove adapters and 467 468 demultiplex LAMP barcodes. Reads were aligned to a custom index containing SARS-CoV-2 469 genome (NC 045512.2), Influenza H1N1 coding sequences (NC 026431.1, NC 026432.1, 470 NC 026433.1, NC 026434.1, NC 026435.1, NC 026436.1, NC 026437.1, NC 026438.1), 471 STATH coding sequence (NM 003154.3), and custom N2 spike sequence (Table S3), target 472 sequences using bowtie2⁴⁶ with options --no-unal and --end-to-end. Alignments with greater than 473 1 mismatch were removed and the number of reads mapping to each target for all barcodes were 474 extracted and output in a matrix. Barcodes with fewer than 25 total mapped reads were discarded.

475 Data Availability

476 Next generation sequencing data generated for this study are available at the NCBI GEO with477 accession GSE172118.

478 **ACKNOWLEDGMENTS**

- 479 The authors thank E. Shields for careful proofreading of analysis scripts; B. Morris and R. Collman
- 480 for the collection and distribution of clinical saliva samples; F. Bushman, S. Sherril-Mix, and
- 481 Abigail Glascock for sharing RT-qPCR data on the clinical samples; the UPenn rapid assay task
- 482 force for project feedback; and the gLAMP weekly forum for advice and guidance.

483 **DISCLOSURE**

R.W-T., C.A.T. and R.B. are inventors on a patent application filed by the University ofPennsylvania related to this work.

486 **REFERENCES**

- 487 1. Haug, N. et al. Ranking the effectiveness of worldwide COVID-19 government
 488 interventions. *Nat Hum Behav* 4, 1303-1312 (2020).
- 489 2. Tian, H. et al. An investigation of transmission control measures during the first 50 days
 490 of the COVID-19 epidemic in China. *Science* 368, 638-642 (2020).
- 491 3. Taipale, J., Romer, P. & Linnarsson, S. Population-scale testing can suppress the spread
 492 of COVID-19. *medRxiv*, 2020.2004.2027.20078329 (2020).
- 493 4. Endo, A., Centre for the Mathematical Modelling of Infectious Diseases, C.-W.G., Abbott,
 494 S., Kucharski, A.J. & Funk, S. Estimating the overdispersion in COVID-19 transmission
 495 using outbreak sizes outside China. *Wellcome Open Res* 5, 67 (2020).
- 496 5. Holt, E. Slovakia to test all adults for SARS-CoV-2. *Lancet* **396**, 1386-1387 (2020).
- 497 6. Larremore, D.B. et al. Test sensitivity is secondary to frequency and turnaround time for
 498 COVID-19 screening. *Sci Adv* (2020).
- Bloom, J.S. et al. Swab-Seq: A high-throughput platform for massively scaled up SARSCoV-2 testing. *medRxiv*, 2020.2008.2004.20167874 (2020).
- 5018.Yelagandula, R. et al. SARSeq, a robust and highly multiplexed NGS assay for parallel502detection of SARS-CoV2 and other respiratory infections. *medRxiv*,5032020.2010.2028.20217778 (2020).
- 5049.Aynaud, M.-M. et al. A Multiplexed, Next Generation Sequencing Platform for High-505Throughput Detection of SARS-CoV-2. *medRxiv*, 2020.2010.2015.20212712 (2020).
- 506 10. Wu, Q. et al. INSIGHT: A population-scale COVID-19 testing strategy combining point-of-507 care diagnosis with centralized high-throughput sequencing. *Sci Adv* **7** (2021).
- 50811.Chappleboim, A. et al. ApharSeq: An Extraction-free Early-Pooling Protocol for Massively509Multiplexed SARS-CoV-2 Detection. *medRxiv*, 2020.2008.2008.20170746 (2020).
- 51012.James, P. et al. LamPORE: rapid, accurate and highly scalable molecular screening for511SARS-CoV-2 infection, based on nanopore sequencing. medRxiv,5122020.2008.2007.20161737 (2020).
- 513 13. Dao Thi, V.L. et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting 514 SARS-CoV-2 RNA in clinical samples. *Sci Transl Med* **12** (2020).
- 515 14. Schmid-Burgk, J.L. et al. LAMP-Seq: Population-Scale COVID-19 Diagnostics Using a Compressed Barcode Space. *bioRxiv*, 2020.2004.2006.025635 (2020).
- 517 15. Li, S. et al. Simultaneous detection and differentiation of dengue virus serotypes 1-4,
 518 Japanese encephalitis virus, and West Nile virus by a combined reverse-transcription
 519 loop-mediated isothermal amplification assay. *Virol J* 8, 360 (2011).
- 520 16. Shirato, K. et al. Detection of Middle East respiratory syndrome coronavirus using reverse 521 transcription loop-mediated isothermal amplification (RT-LAMP). *Virol J* **11**, 139 (2014).

- 522 17. Calvert, A.E., Biggerstaff, B.J., Tanner, N.A., Lauterbach, M. & Lanciotti, R.S. Rapid
 523 colorimetric detection of Zika virus from serum and urine specimens by reverse
 524 transcription loop-mediated isothermal amplification (RT-LAMP). *PLoS One* **12**, e0185340
 525 (2017).
- 526 18. Enomoto, Y. et al. Rapid diagnosis of herpes simplex virus infection by a loop-mediated 527 isothermal amplification method. *J Clin Microbiol* **43**, 951-955 (2005).
- Augustine, R. et al. Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive,
 Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of
 COVID-19 Pandemic. *Biology (Basel)* 9 (2020).
- 531 20. United States Food and Drug Administration. Color Genomics SARS-CoV-2 RT-LAMP
 532 Diagnostic Assay EUA Summary. <u>https://www.fda.gov/media/138249/download</u>.
 533 Published: November 2, 2020, Accessed: December 22, 2020.
- 534 21. Nagamine, K., Hase, T. & Notomi, T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes* **16**, 223-229 (2002).
- 536 22. Notomi, T. et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* **28**, E63 (2000).
- 538 23. Yamagishi, J. et al. Serotyping dengue virus with isothermal amplification and a portable 539 sequencer. *Sci Rep* **7**, 3510 (2017).
- 540 24. Butler, D.J. et al. Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2
 541 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions.
 542 *bioRxiv*, 2020.2004.2020.048066 (2020).
- 54325.Savela, E.S. et al. SARS-CoV-2 is detectable using sensitive RNA saliva testing days544before viral load reaches detection range of low-sensitivity nasal swab tests. *medRxiv*,5452021.2004.2002.21254771 (2021).
- 54626.Ranoa, D.R.E. et al. Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA547Extraction. *bioRxiv*, 2020.2006.2018.159434 (2020).
- 548 27. Myhrvold, C. et al. Field-deployable viral diagnostics using CRISPR-Cas13. *Science* 360, 444-448 (2018).
- 550 28. Lalli, M.A. et al. Rapid and extraction-free detection of SARS-CoV-2 from saliva with colorimetric LAMP. *medRxiv*, 2020.2005.2007.20093542 (2020).
- Rabe, B.A. & Cepko, C. SARS-CoV-2 detection using isothermal amplification and a rapid,
 inexpensive protocol for sample inactivation and purification. *Proc Natl Acad Sci U S A* **117**, 24450-24458 (2020).
- 555 30. Babiker, A., Myers, C.W., Hill, C.E. & Guarner, J. SARS-CoV-2 Testing. *Am J Clin Pathol*556 153, 706-708 (2020).

- 557 31. Satoh, T. et al. Development of mRNA-based body fluid identification using reverse
 558 transcription loop-mediated isothermal amplification. *Anal Bioanal Chem* **410**, 4371-4378
 559 (2018).
- 560 32. MacKay, M.J. et al. The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing. *Nat Biotechnol* **38**, 1021-1024 (2020).
- 562 33. Torres, C. et al. LAVA: an open-source approach to designing LAMP (loop-mediated isothermal amplification) DNA signatures. *BMC Bioinformatics* **12**, 240 (2011).
- 564 34. Zhang, Y. & Tanner, N.A. Development of Multiplexed RT-LAMP for Detection of SARS-565 CoV-2 and Influenza Viral RNA. *medRxiv*, 2020.2010.2026.20219972 (2020).
- 566 35. Takayama, I. et al. Development of real-time fluorescent reverse transcription loop-567 mediated isothermal amplification assay with quenching primer for influenza virus and 568 respiratory syncytial virus. *J Virol Methods* **267**, 53-58 (2019).
- 569 36. Glushakova, L.G. et al. Detection of chikungunya viral RNA in mosquito bodies on cationic (Q) paper based on innovations in synthetic biology. *J Virol Methods* **246**, 104-111 (2017).
- 57137.Kellner, M.J. et al. A rapid, highly sensitive and open-access SARS-CoV-2 detection assay572for laboratory and home testing. *bioRxiv*, 2020.2006.2023.166397 (2020).
- 573 38. Yaren, O. et al. Ultra-rapid detection of SARS-CoV-2 in public workspace environments. *medRxiv*, 2020.2009.2029.20204131 (2020).
- 575 39. Winnett, A. et al. SARS-CoV-2 Viral Load in Saliva Rises Gradually and to Moderate 576 Levels in Some Humans. *medRxiv* (2020).
- 577 40. Pettengill, M.A. & McAdam, A.J. Can We Test Our Way Out of the COVID-19 Pandemic?
 578 *J Clin Microbiol* 58 (2020).
- 579 41. Schuetz, A.N. et al. When Should Asymptomatic Persons Be Tested for COVID-19? *J Clin* 580 *Microbiol* 59 (2020).
- 42. Aschwanden, C. Five reasons why COVID herd immunity is probably impossible. *Nature*582 591, 520-522 (2021).
- 583 43. Everett, J. et al. SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized 584 Patients in Philadelphia. *mBio* **12** (2021).
- 585 I44. Sherrill-Mix, S. et al. LAMP-BEAC: Detection of SARS-CoV-2 RNA Using RT-LAMP and Molecular Beacons. *medRxiv*, 2020.2008.2013.20173757 (2020).
- 58745.Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.5882011 17, 3 (2011).
- 589 46. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods*590 9, 357-359 (2012).
- 591

592 **FIGURE LEGENDS**

593 Figure 1. Barcoding and PCR amplification of RT-LAMP products

(A) Overview of COV-ID. Saliva is collected and inactivated prior to RT-LAMP performed with up
to 96 individual sample barcoded primers. LAMP reactions are pooled and further amplified via
PCR to introduce Illumina adapter sequences and pool-level dual indexes. A single thermal cycler
can amplify 96 or 384 such pools and the resulting "super-pool" can be sequenced overnight to
detect multiple amplicons from 9,216 or 36,864 individual patient samples (number of reads in
parenthesis assume an output of ~450M reads from a NextSeq 500).

(B) Schematic of the RT-LAMP (step I) of COV-ID. Selected numbered intermediates of RT-LAMP reaction are shown to illustrate how the LAMP barcode, shown in yellow, and the P5 and P7 homology sequences (blue and pink, respectively) are introduced in the final LAMP product. Upon generating the dumb-bell intermediate the reaction proceeds through rapid primed and selfprimed extensions to form a mixture of various DNA amplicons containing sequences for PCR amplification. A more detailed version of the LAMP phase of COV-ID, including specific sequences, is illustrated in Fig. S1.

607 (C) Conventional RT-LAMP primers (solid lines) or primers modified for COV-ID (dotted lines)
 608 were used for RT-LAMP of SARS-CoV-2. The numbers of inactivated SARS-CoV-2 virions per
 609 μL is indicated in the color legend.

610 (D) Schematic of the PCR (step II) of COV-ID. Following RT-LAMP, up to 96 reactions are pooled

and purified and Illumina libraries are generated directly by PCR with dual-indexed P5 and P7adapters in preparation for sequencing.

(E) COV-ID primers targeting ACTB mRNA were used for RT-LAMP with HeLa total RNA. LAMP
was diluted 1:100, amplified via PCR and resolved on 2% agarose gel.

615 Figure 2. Sequencing-based detection of SARS-CoV-2 in saliva samples

616 (A) Saliva preparation. Crude saliva was inactivated via TCEP/EDTA addition and 95°C617 incubation prior to RT-LAMP.

618 (B) RT-LAMP followed by COV-ID PCR performed directly on saliva. Saliva with and without

addition of 1,000 copies of inactivated SARS-COV-2 templates was inactivated as described in

620 (A), then used as template.

(C) Alignment of sequenced reads against SARS-COV-2 genome from COV-ID of inactivated
 saliva spiked with without 1,280 virions SARS-COV-2 per μL. All SARS-COV-2 reads align
 exclusively to expected region of the N gene. Open reading frames of viral genome are depicted
 via gray boxes below alignment. Inset: scale shows reads per 1,000.

625 (D) Scatter plot for the ratio of SARS-CoV-2 / (*STATH* + 1) reads obtained by COV-ID (y axis) 626 versus the number of virions per μ L spiked in human saliva (x axis). The threshold was set above 627 the highest values scored in a negative control (dashed line).

(E) COV-ID performed on clinical saliva samples. The scatter plot shows the SARS-CoV-2 /
(STATH + 1) read ratio (*y* axis) versus the viral load in the sample estimated by a clinically
approved, qPCR-based diagnostic test. The threshold was set based on the negative controls
shown in (D).

632 Figure 3. COV-ID multiplex detection of SARS-COV-2 and Influenza A

633 (A) TCEP/EDTA treated saliva was spiked with indicated amounts of BEI heat-inactivated SARS-

- 634 CoV-2 or H1N1 influenza A RNA to the indicated concentration of virions/genomes per μ L. 1 μ l of 635 saliva was used for COV-ID reactions.
- 636 (B) COV-ID was performed in two independent experiments on saliva samples from the matrix 637 shown in (A) in the presence of 20 femtograms synthetic N2 spike-in using N2, influenza34 and 638 STATH COV-ID primers. N2/(N2 Spike + 1) and influenza/(STATH + 1) read ratios are displayed 639 with bars showing median \pm interquartile range. Samples were labeled as positive for a given 640 sequence if the associated read ratio was greater than 2x the maximum value in the control saliva 641 samples.
- 642 (C) Heatmaps of SARS-CoV-2 (left) or H1N1 (right) COV-ID signal in multiplex reaction.
 643 Heatmaps are colored according by percentage of viral reads observed.

644 **Figure 4. Application of COV-ID with paper assay**

- 645 (A) Scheme for COV-ID on viral RNA absorbed on paper.
- 646 (B) PCR reactions from paper samples immersed in water with indicated viral concentrations then
- 647 amplified with *N2* COV-ID primers.
- 648 (C) Scheme for COV-ID on saliva spiked with viral and RNA and absorbed on paper.
- 649 (D) Same as (B) but on saliva absorbed on paper.

- 650 (E) SARS-CoV-2 virus was added to saliva and prepared as in (C). RT-LAMP and sequencing
- 651 was carried out in presence of SARS spike-in RNA. Viral reads are presented as ratio against the
- 652 sum of STATH and N2 spike-in reads. Positive threshold was set as 2x maximum value in
- 653 negative saliva and indicated by dashed horizontal line.
- 654 (F–G): Paper-based COV-ID workflow (F) and cost calculations (G). Saliva is collected orally on
- a precut strip of paper, from which a 2 mm square would be cut out and added to a reaction vessel
- 656 containing TCEP/EDTA inactivation buffer and processed as shown in (C).
- 657

659 SUPPLEMENTARY FIGURE LEGENDS

660 Figure S1. Detailed COV-ID mechanism

661 Steps of COV-ID protocol are depicted, showing RT-LAMP mechanism and ultimate amplicon 662 that is sequenced. For clarity only selected steps of RT-LAMP reaction are shown and loop primer

663 intermediates are not depicted. For full LAMP mechanism see ²¹.

664 Figure S2. Optimization of COV-ID in human saliva

- (A) Saliva COV-ID sequence validation. Single saliva COV-ID reaction using *N2* primers wassequenced by the Sanger method.
- 667 (B) Validation of control human amplicons for RT-LAMP on saliva. RT-LAMP of TCEP/EDTA
- inactivated saliva was performed with conventional RT-LAMP primer sets for ACTB and STATH
 in the presence or absence of RNase A.
- 670 (C) Characterization of COV-ID sequencing libraries. Breakdown of reads for sequence data
- 671 presented in Fig. 2D. Samples without added template consist of predominantly adapter dimers.
- (D) Validation of COV-ID LAMP barcodes. 32 potential barcodes were tested for LAMP primersets indicated, incompatible barcodes are marked in red.
- (E) Validation of pooled PCR. COV-ID was performed on saliva samples using unique LAMP
 barcodes. The RT-LAMP reactions were then amplified either by individual PCR or by first pooling
 and then performing a single PCR on the pool.
- 677 Figure S3. RT-LAMP amplification of SARS-CoV-2 spike-in RNA
- 678 (A) Synthetic *N2* Spike RNA. SARS-CoV-2 *N2* RNA fragment was synthesized including 7 nt
 679 divergent sequence inside the forward loop primer-binding site, maintaining all other LAMP primer
 680 binding sites and identical GC content.
- (B) RT-LAMP using COV-ID *N2* primers was carried out on indicated amounts of spike-in RNA,
- showing rapid amplification down to picogram quantities of added template.
- (C) Total number of reads per barcode in COV-ID pool obtained by including (+) or omitting (-)the *N2* spike-in.
- 685 (D) Spurious COV-ID signal for the *N2* amplicon in negative control samples after normalization
- either to the *STATH* control in absence of spike-in (left) or to the *N2* spike-in control.



Figure 1. Barcoding and PCR amplification of RT-LAMP products

(A) Overview of COV-ID. Saliva is collected and inactivated prior to RT-LAMP performed with up to 96 individual sample barcoded primers. LAMP reactions are pooled and further amplified via PCR to introduce Illumina adapter sequences and pool-level dual indexes. A single thermal cycler can amplify 96 or 384 such pools and the resulting "super-pool" can be sequenced overnight to detect multiple amplicons from 9,216 or 36,864 individual patient samples (number of reads in parenthesis assume an output of ~450M reads from a NextSeq 500).

(B) Schematic of the RT-LAMP (step I) of COV-ID. Selected numbered intermediates of RT-LAMP reaction are shown to illustrate how the LAMP barcode, shown in yellow, and the P5 and P7 homology sequences (blue and pink, respectively) are introduced in the final LAMP product. Upon generating the dumb-bell intermediate the reaction proceeds through rapid primed and self-primed extensions to form mixture of various DNA amplicons containing sequences for PCR amplification. A more detailed version of the LAMP phase of COV-ID, including specific sequences, is illustrated in Fig. S1.

(C) Conventional RT-LAMP primers (solid lines) or primers modified for COV-ID (dotted lines) were used for RT-LAMP of SARS-CoV-2. The numbers of inactivated SARS-CoV-2 virions per μ L is indicated in the color legend.

(D) Schematic of the PCR (step II) of COV-ID. Following RT-LAMP, up to 96 reactions are pooled and purified and Illumina libraries are generated directly by PCR with dual-indexed P5 and P7 adapters in preparation for sequencing.

(E) COV-ID primers targeting ACTB mRNA were used for RT-LAMP with HeLa total RNA. LAMP was diluted 1:100, amplified via PCR and resolved on 2% agarose gel.



Figure 2. Sequencing-based detection of SARS-CoV-2 in saliva samples

(A) Saliva preparation. Crude saliva was inactivated via TCEP/EDTA addition and 95°C incubation prior to RT-LAMP.

(B) RT-LAMP followed by COV-ID PCR performed directly on saliva. Saliva with and without addition of 1,000 copies of inactivated SARS-COV-2 templates was inactivated as described in (A), then used as template.

(C) Alignment of sequenced reads against SARS-COV-2 genome from COV-ID of inactivated saliva spiked with without 1,280 virions SARS-COV-2 per µL. All SARS-COV-2 reads align exclusively to expected region of the N gene. Open reading frames of viral genome are depicted via gray boxes below alignment. Inset: scale shows reads per 1,000.

(D) Scatter plot for the ratio of SARS-CoV-2 / (STATH + 1) reads obtained by COV-ID (y axis) versus the number of virions per μ L spiked in human saliva (x axis). The threshold was set above the highest values scored in a negative control (dashed line).

(E) COV-ID performed on clinical saliva samples. The scatter plot shows the SARS-CoV-2 / (STATH + 1) read ratio (y axis) versus the viral load in the sample estimated by a clinically approved, qPCR-based diagnostic test. The threshold was set based on the negative controls shown in (D).



Figure 3. COV-ID multiplex detection of SARS-COV-2 and Influenza A

(A) TCEP/EDTA treated saliva was spiked with indicated amounts of BEI heat-inactivated SARS-CoV-2 or H1N1 influenza A RNA to the indicated concentration of virions/genomes per μ L. 1 μ I of saliva was used for COV-ID reactions.

(B) COV-ID was performed in two independent experiments on saliva samples from the matrix shown in (A) in the presence of 20 femtograms synthetic N2 spike-in using N2, influenza (Zhang and Tanner, 2020) and STATH COV-ID primers. N2/(N2 Spike + 1) and influenza/(STATH + 1) read ratios are displayed with bars showing median ± interquartile range.

(C) Heatmaps of SARS-CoV-2 (left) or H1N1 (right) COV-ID signal in multiplex reaction. Heatmaps are colored according by percentage of viral reads observed.



PCR pools	Total samples	Total Reads (Nextseq)	Reads/sample	Sequencing cost/sample
96	9,216	450,000,000	~48,000	\$0.16
384	36,864	450,000,000	~12,000	\$0.04

Figure 4. COV-ID on saliva collected on paper

(A) Scheme for COV-ID on viral RNA absorbed on paper.

(B) PCR reactions from paper samples immersed in water with indicated viral concentrations then amplified with N2 COV-ID primers.

(C) Scheme for COV-ID on saliva spiked with viral and RNA and absorbed on paper.

(D) Same as (B) but on saliva absorbed on paper.

(E) SARS-CoV-2 virus was added to saliva and prepared as in (C). RT-LAMP and sequencing was carried out in presence of SARS spike-in RNA. Viral reads are presented as ratio against the sum of STATH and N2 spike-in reads. Positive threshold was set as 2x maximum value in negative saliva and indicated by dashed horizontal line.

(F–G): Paper-based COV-ID workflow (F) and cost calculations (G). Saliva is collected orally on a precut strip of paper, from which a 2 mm square would be cut out and added to a reaction vessel containing TCEP/EDTA inactivation buffer and processed as shown in (C).



Figure S1. Detailed COV-ID mechanism

The steps of the COV-ID protocol are depicted, showing RT-LAMP mechanism and the final barcoded amplicon that is sequenced. For clarity only, selected steps of RT-LAMP reaction are shown and loop primer intermediates are not depicted. For full LAMP mechanism see (Nagamine et al., 2002).



Figure S2. Optimization of COV-ID in human saliva

(A) Saliva COV-ID sequence validation. Single saliva COV-ID reaction using N2 primers was sequenced by the Sanger method.

(B) Validation of control human amplicons for RT-LAMP on saliva. RT-LAMP of TCEP/EDTA inactivated saliva was performed with conventional RT-LAMP primer sets for ACTB and STATH in the presence or absence of RNase A.

(C) Characterization of COV-ID sequencing libraries. Breakdown of reads for sequence data presented in Fig. 2D. Samples without added template consist of predominantly adapter dimers.

(D) Validation of COV-ID LAMP barcodes. 32 potential barcodes were tested for LAMP primer sets indicated, incompatible barcodes are marked in red.

(E) Validation of pooled PCR. COV-ID was performed on saliva samples using unique LAMP barcodes. The RT-LAMP reactions were then amplified either by individual PCR or by first pooling and then performing a single PCR on the pool.



Figure S3. Spike-in strategy for COV-ID`

(A) Synthetic N2 Spike RNA. SARS-CoV-2 N2 RNA fragment was synthesized including 7 nt divergent sequence inside the forward loop primer-binding site, maintaining all other LAMP primer binding sites and identical GC content.

(B) RT-LAMP using COV-ID N2 primers was carried out on indicated amounts of spike-in RNA, showing rapid amplification down to picogram quantities of added template.

(C) Total number of reads per barcode in COV-ID pool obtained by including (+) or omitting (-) the N2 spike-in.

(D) Spurious COV-ID signal for the N2 amplicon in negative control samples after normalization either to the STATH control in absence of spike-in (left) or to the N2 spike-in control.